GAFA
RDHL

Garton & Associates Financial Advisors’s Redhill Biopharma RDHL Stock Holding History

Garton & Associates Financial Advisors’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15
Closed -$15 – 569
2025
Q4 		$15 Buy
+15
New +$20 ﹤0.01% 1169

Other funds holding RDHL

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Garton & Associates Financial Advisors's RDHL Position: Q1 2026 in Review

Garton & Associates Financial Advisors sold out of Redhill Biopharma (RDHL) in Q1 2026, closing a stake of 15 shares — an estimated $15 sold.

Garton & Associates Financial Advisors first reported a position in RDHL in Q4 2025 and held it in 1 quarter. The position peaked at $15 in Q4 2025. 16 funds tracked by Wall St. Rank hold RDHL as of Q1 2026.

  • Garton & Associates Financial Advisors reported no remaining Redhill Biopharma position as of Q1 2026 after selling out during the quarter.
  • Garton & Associates Financial Advisors sold 15 Redhill Biopharma shares in Q1 2026, an estimated $15.
  • Garton & Associates Financial Advisors first reported a position in Redhill Biopharma in Q4 2025 and held it in 1 quarter.
  • Garton & Associates Financial Advisors's Redhill Biopharma position peaked at $15 in Q4 2025.
  • 16 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2026.

Based on Garton & Associates Financial Advisors's 13F filing for Q1 2026, filed 11 May 2026.